Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS: Zutectra in liver-transplanted patients
2012-002516-51Phase 3Completed
- Sponsor
- Biotest AG
- Start
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hepatitis B immune globulin in hepatitis B (HBV) and Hepatitis B reactivation (HBVr), sponsored by Biotest AG. Primary endpoint: Primary efficacy and failure rate at 24 weeks. Started Jun 2012; status: completed.
02
Drugs
hepatitis B immune globulin
03
Conditions
hepatitis B (HBV)Hepatitis B reactivation (HBVr)
Beyond the preview
Go deeper on 2012-002516-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002516-51.